Advertisement

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study

  • Adi Aran
  • Hanoch Cassuto
  • Asael Lubotzky
  • Nadia Wattad
  • Esther Hazan
Brief Report

Abstract

Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0–17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.

Keywords

Cannabidiol Medical cannabis Medical marijuana Autism spectrum disorder Disruptive behavior 

Notes

Author Contributions

AA: Study conception and design; acquisition, analysis and interpretation of data; drafted manuscript; critically revised manuscript and gave final approval. CH and LA: Study conception; interpretation of data; critically revised manuscript and gave final approval. WN: Study design; acquisition of data; critically revised manuscript and gave final approval. EH: Study design; acquisition, analysis and interpretation of data; drafted manuscript; critically revised manuscript and gave final approval.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Compliance with Ethical Standards

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

10803_2018_3808_MOESM1_ESM.docx (28 kb)
Supplementary material (DOCX 27 KB)

References

  1. Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., et al. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106.  https://doi.org/10.1177/1362361314524641.CrossRefPubMedGoogle Scholar
  2. Ballaban-Gil, K., & Tuchman, R. (2000). Epilepsy and epileptiform EEG: Association with autism and language disorders. Mental Retardation and Developmental Disabilities Research Reviews, 6(4), 300–308,  https://doi.org/10.1002/1098-2779(2000)6:4%3C300::aid-mrdd9%3E3.0.co;2-r.CrossRefPubMedGoogle Scholar
  3. Campos, A. C., Fogaca, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., et al. (2017). Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Frontiers in Pharmacology, 8, 269.  https://doi.org/10.3389/fphar.2017.00269.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Chakrabarti, B., & Baron-Cohen, S. (2011). Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces. Molecular Autism, 2(1), 10.  https://doi.org/10.1186/2040-2392-2-10.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., et al. (2017). Trial of Cannabidiol for drug-resistant seizures in the dravet syndrome. The New England Journal of Medicine, 376(21), 2011–2020.  https://doi.org/10.1056/NEJMoa1611618.CrossRefPubMedGoogle Scholar
  6. Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., et al. (2018). Effect of Cannabidiol on drop seizures in the lennox-gastaut syndrome. The New England Journal of Medicine, 378(20), 1888–1897.  https://doi.org/10.1056/NEJMoa1714631.CrossRefPubMedGoogle Scholar
  7. Gururajan, A., Taylor, D. A., & Malone, D. T. (2012). Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. The Journal of Psychopharmacology, 26(10), 1317–1332.  https://doi.org/10.1177/0269881112441865.CrossRefPubMedGoogle Scholar
  8. Hofer, J., Hoffmann, F., & Bachmann, C. (2017). Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review. Autism, 21(4), 387–402.  https://doi.org/10.1177/1362361316646559.CrossRefPubMedGoogle Scholar
  9. Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America, 114(42), 11229–11234.  https://doi.org/10.1073/pnas.1711351114.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., et al. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9, 18.  https://doi.org/10.1186/s13229-018-0203-y.CrossRefPubMedPubMedCentralGoogle Scholar
  11. King, B. H., Dukes, K., Donnelly, C. L., Sikich, L., McCracken, J. T., Scahill, L., et al. (2013). Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial. JAMA Pediatrics, 167(11), 1045–1052.  https://doi.org/10.1001/jamapediatrics.2013.2698.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Lee, B. H., Smith, T., & Paciorkowski, A. R. (2015). Autism spectrum disorder and epilepsy: Disorders with a shared biology. Epilepsy & Behavior, 47, 191–201.  https://doi.org/10.1016/j.yebeh.2015.03.017.CrossRefGoogle Scholar
  13. Maskey, M., Warnell, F., Parr, J. R., Le Couteur, A., & McConachie, H. (2013). Emotional and behavioural problems in children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 43(4), 851–859.  https://doi.org/10.1007/s10803-012-1622-9.CrossRefPubMedGoogle Scholar
  14. Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior, 70(Pt B), 319–327.  https://doi.org/10.1016/j.yebeh.2016.11.006.CrossRefGoogle Scholar
  15. Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391(10125), 1085–1096.  https://doi.org/10.1016/s0140-6736(18)30136-3.CrossRefPubMedGoogle Scholar
  16. Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences.  https://doi.org/10.3390/ijms18091916.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Neuropediatric UnitShaare Zedek Medical CenterJerusalemIsrael
  2. 2.Clallit HMO (Kupat Holim)JerusalemIsrael

Personalised recommendations